Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients

Table 3

RAVs to HCV NS5A inhibitors.

Resistance mutations	Drugs	References	Detected resistance mutations; (HCV 6a )	Detected resistance mutations; (HCV 1b )
M28T/A/G/V	Daclatasvir, ombitasvir, ledipasvir	[13, 14, 30, 31]	M28L 85.2% (75/88); M28F 13.6% (12/88)	M28L 98.31% (58/59)
Q30E/R/H/L/T	Daclatasvir, ombitasvir, ledipasvir	[13, 14, 30, 31]	Q30R 93.2% (82/88)	Q30R 57.63% (34/59)
L31M/V/I/F	Daclatasvir, ombitasvir, ledipasvir	[13, 30–32]	L31M 4.6% (4/88)	L31M 1.69% (1/59)
H54Y	Daclatasvir	[33]	H54Q 1.1% (1/88); H54T 3.4% (3/88); H54S 1.1% (1/88)	H54Q 83.05% (49/59)
H58P	Daclatasvir	[33]	H58P 6.8% (6/88); H58T 93.2% (82/88)	H58P 86.44% (51/59); H58T 3.39% (2/59); H58S 6.78% (4/59); H58R 3.39% (2/59)
Y93C/N/F/H/S	Daclatasvir, ombitasvir, ledipasvir	[13, 14, 30–33]	Y93A 47.7% (42/88); Y93T 46.6% (41/88)	Y93H 5.08% (3/59); Y93T 1.69% (1/59); Y93A 20.34% (12/59)